{
    "id": 14108,
    "fullName": "CD79A act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CD79A act mut indicates that this variant results in a gain of function in the Cd79a protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 973,
        "geneSymbol": "CD79A",
        "terms": [
            "CD79A",
            "IGA",
            "MB-1"
        ]
    },
    "variant": "act mut",
    "createDate": "11/20/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7346,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring a CD79A activating mutation demonstrated sensitivity to treatment with BHA536, resulting in decreased cell growth (PMID: 21324920).",
            "molecularProfile": {
                "id": 14364,
                "profileName": "CD79A act mut"
            },
            "therapy": {
                "id": 4475,
                "therapyName": "BHA536",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3976,
                    "pubMedId": 21324920,
                    "title": "Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21324920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7345,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring a CD79A activating mutation demonstrated sensitivity to treatment with Sotrastaurin (AEB071), resulting in decreased cell growth (PMID: 21324920).",
            "molecularProfile": {
                "id": 14364,
                "profileName": "CD79A act mut"
            },
            "therapy": {
                "id": 621,
                "therapyName": "AEB071",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3976,
                    "pubMedId": 21324920,
                    "title": "Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21324920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14364,
            "profileName": "CD79A act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 7139,
                    "name": "PKC Inhibitor (Pan)",
                    "profileName": "CD79A act mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}